McKesson Corporation $MCK Shares Bought by Schroder Investment Management Group

Schroder Investment Management Group lifted its stake in McKesson Corporation (NYSE:MCK) by 4.2% in the third quarter, HoldingsChannel reports. The fund owned 153,087 shares of the company’s stock after purchasing an additional 6,213 shares during the quarter. Schroder Investment Management Group’s holdings in McKesson were worth $118,266,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the business. ProVise Management Group LLC raised its holdings in McKesson by 4.2% during the 3rd quarter. ProVise Management Group LLC now owns 14,558 shares of the company’s stock worth $11,247,000 after buying an additional 585 shares during the period. Pinnacle Associates Ltd. increased its stake in shares of McKesson by 5.3% in the third quarter. Pinnacle Associates Ltd. now owns 2,620 shares of the company’s stock worth $2,024,000 after acquiring an additional 132 shares during the last quarter. B. Metzler seel. Sohn & Co. AG raised its stake in shares of McKesson by 13.4% during the 3rd quarter. B. Metzler seel. Sohn & Co. AG now owns 6,860 shares of the company’s stock worth $5,300,000 after purchasing an additional 808 shares in the last quarter. Rathbones Group PLC raised its holdings in shares of McKesson by 1.1% during the 3rd quarter. Rathbones Group PLC now owns 55,769 shares of the company’s stock valued at $43,084,000 after purchasing an additional 612 shares in the last quarter. Finally, Vinva Investment Management Ltd grew its holdings in McKesson by 22.8% during the third quarter. Vinva Investment Management Ltd now owns 10,492 shares of the company’s stock valued at $7,993,000 after purchasing an additional 1,951 shares during the last quarter. 85.07% of the stock is currently owned by institutional investors.

McKesson Stock Performance

Shares of MCK stock opened at $941.19 on Tuesday. The company has a market capitalization of $115.29 billion, a price-to-earnings ratio of 27.07, a PEG ratio of 1.48 and a beta of 0.38. McKesson Corporation has a 52 week low of $633.53 and a 52 week high of $999.00. The company has a 50-day simple moving average of $884.77 and a 200 day simple moving average of $819.18.

McKesson (NYSE:MCK) last announced its earnings results on Wednesday, February 4th. The company reported $9.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.19 by $0.15. The firm had revenue of $106.16 billion for the quarter, compared to analyst estimates of $105.98 billion. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The business’s revenue was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $8.03 EPS. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Sell-side analysts forecast that McKesson Corporation will post 32.77 EPS for the current year.

McKesson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 1st. Stockholders of record on Monday, March 2nd will be paid a $0.82 dividend. The ex-dividend date of this dividend is Monday, March 2nd. This represents a $3.28 annualized dividend and a dividend yield of 0.3%. McKesson’s dividend payout ratio is currently 9.43%.

Analyst Upgrades and Downgrades

MCK has been the subject of a number of research analyst reports. Barclays upped their price target on McKesson from $960.00 to $1,050.00 and gave the stock an “overweight” rating in a report on Wednesday, February 18th. Zacks Research cut McKesson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, November 25th. TD Cowen increased their price target on McKesson from $1,000.00 to $1,012.00 and gave the stock a “buy” rating in a research report on Thursday, February 5th. Weiss Ratings cut shares of McKesson from a “buy (a-)” rating to a “buy (b+)” rating in a research report on Thursday, February 5th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of McKesson in a research note on Wednesday, December 10th. Thirteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $960.93.

Insider Activity

In other McKesson news, EVP Thomas L. Rodgers sold 276 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $816.18, for a total value of $225,265.68. Following the completion of the sale, the executive vice president owned 2,268 shares of the company’s stock, valued at approximately $1,851,096.24. This trade represents a 10.85% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CAO Napoleon B. Rutledge, Jr. sold 328 shares of the firm’s stock in a transaction that occurred on Friday, February 6th. The shares were sold at an average price of $955.00, for a total value of $313,240.00. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 3,868 shares of company stock valued at $3,743,820. 0.08% of the stock is currently owned by company insiders.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.